Tessera Defense and Homeland Security (HLSQ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Sep, 2026Executive summary
Special Meeting scheduled for October 20, 2026, to vote on amending the 2026 Equity Incentive Plan and a potential adjournment proposal.
Amendment seeks to increase shares reserved for equity awards from 685,000 to 6,000,000 post-reverse split.
Board recommends voting FOR both proposals, citing business needs and competitive compensation.
Recent acquisitions and anticipated growth drive need for additional equity awards.
Voting matters and shareholder proposals
Proposal 1: Approve amendment to increase equity plan shares by 5,315,000 (to 6,000,000 total, post-split).
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit proxies.
Only stockholders of record as of October 5, 2026, may vote; each share gets one vote.
Both proposals require a majority of votes cast for approval.
Board unanimously recommends voting FOR both proposals.
Board of directors and corporate governance
Current board includes Michael Oster (CEO), David Rokach (CFO), Roy Timor-Rousso (Chief Business Officer), and four directors with finance and investment backgrounds.
Three directors qualify as independent under NYSE American standards; one is not independent due to related board service.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, chaired by independent directors.
Latest events from Tessera Defense and Homeland Security
- First defense-tech revenue reported post-acquisitions, but liquidity and going concern risks persist.HLSQ
Q2 2026 - Proxy seeks approval for DFSL acquisition securities, reverse split, and auditor ratification.HLSQ
Proxy filing - Stockholders to vote on acquisition-related securities issuance, reverse split, and auditor change.HLSQ
Proxy filing - Shifted to defense/security tech, offering resale shares from acquisitions, with high dilution and financial risk.HLSQ
Registration filing - No auditor appointed for 2026; voting matters for the annual meeting remain unchanged.HLSQ
Proxy filing - Integrated AI and LADAR solutions drive growth in defense and security markets.HLSQ
Investor presentation - Vote on director election, equity plan amendment, and adjournment; board recommends approval.HLSQ
Proxy filing - Merger, $50M financing, and clinical progress drive 2025 milestones amid ongoing losses and delisting risk.HLSQ
Q2 2024 - BX211 and BX004 show strong efficacy; $12M financing supports key clinical milestones.HLSQ
Q4 2024 & Study Result